Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308834322> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4308834322 endingPage "167" @default.
- W4308834322 startingPage "159" @default.
- W4308834322 abstract "Pexidartinib is an oral small-molecule tyrosine kinase inhibitor that selectively targets colony-stimulating factor 1 receptor. Two phase 1 single-center trials were conducted in healthy subjects to determine the absorption, distribution, metabolism, and excretion of pexidartinib using radiolabeled drug and to assess the dose proportionality of pexidartinib following single oral doses. In the mass balance study, eight male subjects received a single oral dose of [14 C]-pexidartinib 400 mg with radioactivity assessed in plasma, urine, and feces samples taken at various timepoints postdose. In the dose-proportionality study, 18 subjects received single doses of pexidartinib 200, 400, and 600 mg using randomization sequences. Peak pexidartinib and total radioactivity were observed at 1.75-2.0 hours after the oral dose and then declined in a multiphasic manner. The overall mean recovery of administered radioactivity was 92.2% over 240 hours with 64.8% in the feces and 27.4% in the urine. Major components detected in plasma were pexidartinib and glucuronide (M5, ZAAD-1006a), with M5 and pexidartinib detected in urine and feces, respectively. A glucuronide of dealkylated form (M1) in the urine and multiple oxidized forms (M2, M3, and M4) in feces were detected. The dose-proportionality study found dose-proportional drug exposure between the 200- and 400-mg doses and slightly less than proportional exposure between the 400- and 600-mg doses. These results from these studies provide insight into pexidartinib disposition after oral administration and support the development of dosing guidance in subjects with renal or hepatic impairment or subjects taking cytochrome P450 3A and uridine disphosphate-glucuronosyl transferase inhibitors and inducers." @default.
- W4308834322 created "2022-11-17" @default.
- W4308834322 creator A5000968753 @default.
- W4308834322 creator A5017421941 @default.
- W4308834322 creator A5018268843 @default.
- W4308834322 creator A5048278301 @default.
- W4308834322 creator A5063374906 @default.
- W4308834322 creator A5072034622 @default.
- W4308834322 creator A5087648612 @default.
- W4308834322 date "2022-11-11" @default.
- W4308834322 modified "2023-09-26" @default.
- W4308834322 title "Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality" @default.
- W4308834322 cites W2919838351 @default.
- W4308834322 cites W2951817901 @default.
- W4308834322 cites W3017806677 @default.
- W4308834322 cites W3040119763 @default.
- W4308834322 cites W3086166882 @default.
- W4308834322 cites W3092108627 @default.
- W4308834322 cites W4210769315 @default.
- W4308834322 cites W4220806346 @default.
- W4308834322 cites W982662479 @default.
- W4308834322 doi "https://doi.org/10.1002/cpdd.1186" @default.
- W4308834322 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36369799" @default.
- W4308834322 hasPublicationYear "2022" @default.
- W4308834322 type Work @default.
- W4308834322 citedByCount "1" @default.
- W4308834322 countsByYear W43088343222023 @default.
- W4308834322 crossrefType "journal-article" @default.
- W4308834322 hasAuthorship W4308834322A5000968753 @default.
- W4308834322 hasAuthorship W4308834322A5017421941 @default.
- W4308834322 hasAuthorship W4308834322A5018268843 @default.
- W4308834322 hasAuthorship W4308834322A5048278301 @default.
- W4308834322 hasAuthorship W4308834322A5063374906 @default.
- W4308834322 hasAuthorship W4308834322A5072034622 @default.
- W4308834322 hasAuthorship W4308834322A5087648612 @default.
- W4308834322 hasBestOaLocation W43088343221 @default.
- W4308834322 hasConcept C112705442 @default.
- W4308834322 hasConcept C126322002 @default.
- W4308834322 hasConcept C151730666 @default.
- W4308834322 hasConcept C2777056448 @default.
- W4308834322 hasConcept C2777288759 @default.
- W4308834322 hasConcept C2779186261 @default.
- W4308834322 hasConcept C2780026642 @default.
- W4308834322 hasConcept C61716771 @default.
- W4308834322 hasConcept C71924100 @default.
- W4308834322 hasConcept C86803240 @default.
- W4308834322 hasConcept C98274493 @default.
- W4308834322 hasConceptScore W4308834322C112705442 @default.
- W4308834322 hasConceptScore W4308834322C126322002 @default.
- W4308834322 hasConceptScore W4308834322C151730666 @default.
- W4308834322 hasConceptScore W4308834322C2777056448 @default.
- W4308834322 hasConceptScore W4308834322C2777288759 @default.
- W4308834322 hasConceptScore W4308834322C2779186261 @default.
- W4308834322 hasConceptScore W4308834322C2780026642 @default.
- W4308834322 hasConceptScore W4308834322C61716771 @default.
- W4308834322 hasConceptScore W4308834322C71924100 @default.
- W4308834322 hasConceptScore W4308834322C86803240 @default.
- W4308834322 hasConceptScore W4308834322C98274493 @default.
- W4308834322 hasIssue "2" @default.
- W4308834322 hasLocation W43088343221 @default.
- W4308834322 hasLocation W43088343222 @default.
- W4308834322 hasLocation W43088343223 @default.
- W4308834322 hasOpenAccess W4308834322 @default.
- W4308834322 hasPrimaryLocation W43088343221 @default.
- W4308834322 hasRelatedWork W1999208146 @default.
- W4308834322 hasRelatedWork W2004325424 @default.
- W4308834322 hasRelatedWork W2006342447 @default.
- W4308834322 hasRelatedWork W2025990812 @default.
- W4308834322 hasRelatedWork W2095943039 @default.
- W4308834322 hasRelatedWork W2587902810 @default.
- W4308834322 hasRelatedWork W2613078211 @default.
- W4308834322 hasRelatedWork W2793520024 @default.
- W4308834322 hasRelatedWork W2996498483 @default.
- W4308834322 hasRelatedWork W3021369409 @default.
- W4308834322 hasVolume "12" @default.
- W4308834322 isParatext "false" @default.
- W4308834322 isRetracted "false" @default.
- W4308834322 workType "article" @default.